Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib with or without ceralasertib in metastatic triple-negative breast cancer stratified by HRR gene status
NL-OMON50520Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Olaparib monotherapy, Ceralasertib + olaparib and AZD1775 + olaparib (3 arms). Primary endpoints: Progression-free survival and Progression-free survival by investigator assessment. Started Apr 2019; status: active, not recruiting.
02
Drugs
olaparibceralasertibadavosertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON50520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50520.